

ESC Highlights 2021



September 22
7:30 – 9:00 pm EST



Developed by:



ESC 2021 Highlights: Live Webcast

This program will cover the key clinical trial findings and their implications from ESC 2021. This program is intended for cardiovascular specialists and primary care physicians from across Canada.



CO-CHAIRS

Milan Gupta,
MD, FRCPC, FCCS, CPC(HC)
Associate Clinical Professor
McMaster University
Medical Director, Canadian
Collaborative Research Network
Brampton, ON



CO-CHAIRS

Narendra Singh,
MD, FRCPC, FCCS, FACC, FAHA
Director, NSC Cardiology
Clinical Assistant Professor,
Medical College of Georgia at
Augusta University and Mercer
University
Atlanta, GA

This program was developed by CCRN and received an unrestricted educational grant from HLS Therapeutics, Novo Nordisk, Amgen, Bayer, and Boehringer Ingelheim/Eli Lilly Alliance

Discussion Topics:

Explore the latest major trial updates from the ESC including:

- EMPEROR-Preserved:** SGLT2 inhibition in heart failure with preserved ejection fraction
- FIGARO-DKD/FIDELIO:** Effects of Finerenone in cardiorenal protection
- HUYGENS:** Effects of evolocumab on coronary plaque characteristics
- REDUCE-IT PRIOR MI** - effects of icosapent ethyl in patients with prior MI

Plus: Latest trials in COVID-19, thrombosis, and risk factor management

Learning Objectives:

Following participation in this program, participants will be able to:

- Identify the clinical implications of the new data presented at ESC 2021
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice



Register Now!
www.ccrnmd.com



www.ccrnmd.com